Third Harmonic Bio to Participate in the Morgan Stanley Global Healthcare Conference
31 Agosto 2023 - 2:30PM
Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical
company focused on advancing the next wave of medicine for
inflammatory diseases, today announced that Chief Executive Officer
Natalie Holles will participate in a fireside chat at the Morgan
Stanley Global Healthcare Conference on Tuesday, September 12,
2023, from 7:30-7:55 a.m. ET.
A live audio webcast will be available within the Investors
and Media section of the Third Harmonic Bio website. An
archived replay will be accessible for 90 days following the
event.
About Third Harmonic Bio, Inc.Third Harmonic
Bio is a biopharmaceutical company focused on advancing the next
wave of medicine for inflammatory diseases through the development
of novel highly selective, oral small-molecule inhibitors of KIT, a
cell surface receptor that serves as the master regulator of mast
cell function and survival. Early clinical studies demonstrate that
KIT inhibition has the potential to revolutionize the treatment of
a broad range of mast-cell-mediated inflammatory diseases, and that
a titratable, oral, intracellular small molecule inhibitor may
provide the optimal therapeutic profile against this target. Third
Harmonic’s lead product candidate THB335 is expected to enter
clinical trials during the first half of 2024. For more
information, please visit the Third Harmonic Bio
website: www.thirdharmonicbio.com.
Investor Contact:Bob
Horho@thirdharmonicbio.com
Grafico Azioni Third Harmonic Bio (NASDAQ:THRD)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Third Harmonic Bio (NASDAQ:THRD)
Storico
Da Set 2023 a Set 2024